Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing

Cancer Gene Therapy

Volumn 10, Issue 5, 2003, Pages 353-364

  Wiewrodt, Rainer ^a   Amin, Kunjlata ^b   Kiefer, Michael ^a   Jovanovic, Vuk P ^a   Kapoor, Veena ^a   Force, Seth ^b   Chang, Michael ^b   Lanuti, Michael ^b   Black, Margaret E ^c   Kaiser, Larry R ^b   Albelda, Steven M ^a,d  

^a Division of Pulmonary Allergy and Critical Care Medicine   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c WASHINGTON STATE UNIVERSITY   (United States)

^d 856 BRB II/III ^*  (United States)

Author keywords

Gene therapy; Lung cancer; Mesothelioma; Suicide gene therapy; Thymidine kinase

Indexed keywords

ADENOVIRUS VECTOR; GANCICLOVIR; THYMIDINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL ASSAY; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FIBROSARCOMA; GENE EXPRESSION; GENE INSERTION; GENE SEQUENCE; GENE TRANSFER; GENETIC ENGINEERING; GENETIC RECOMBINATION; GENETIC TRANSDUCTION; GLIOMA CELL; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS DM30; HERPES SIMPLEX VIRUS SR39; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MESOTHELIOMA; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; RAT; SOLID TUMOR; STEM CELL TRANSPLANTATION; SUICIDE GENE THERAPY; TUMOR CELL; TUMOR CELL LINE; UTERINE CERVIX CARCINOMA; VIRAL GENE DELIVERY SYSTEM; VIRUS MUTANT; VIRUS RECOMBINANT; WILD TYPE;

ADENOVIRIDAE; ANIMALS; ANTIVIRAL AGENTS; APOPTOSIS; BINDING SITES; FEMALE; GANCICLOVIR; GENE TRANSFER TECHNIQUES; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; MICE; MICE, INBRED BALB C; MICE, SCID; MUTAGENESIS; NEOPLASMS; PRODRUGS; RATS; THYMIDINE KINASE; TRANSFECTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; ANIMALIA; HUMAN HERPESVIRUS 1; INSERTION SEQUENCES; SIMPLEXVIRUS;

EID: 12444263241     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700589     Document Type: Article

References (38)

1. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986;46:5276-5281.
2. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992;256:1550-1552.
3. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53:5274-5283.
4. Albelda SM, Wiewrodt R, Zuckerman JB. Gene therapy for lung disease: hype or hope? Ann Intern Med. 2000;132:649-660.
5. Smythe WR, Kaiser LR, Hwang HC, Amin KM, Pilewski JM, Eck SJ, et al. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg. 1994;57:1395-1401.
6. Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber K, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther. 1998;9:1083-1092.
7. O'Malley Jr BW, Chen SH, Schwartz MR, Woo SL. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res. 1995;55:1080-1085.
8. Freeman SM, McCune C, Robinson W, Abboud CN, Abraham GN, Angel C, et al. The treatment of ovarian cancer with a gene modified cancer vaccine: a phase I study. Hum Gene Ther. 1995;6:927-939.
9. Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel GJ, et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science. 1994;265:781-784.
10. Cohen JL, Boyer O, Salomon B, Onclercq R, Charlotte F, Bruel S, et al. Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes. Blood. 1997;89:4636-4645.
11. Caruso M, Salomon B, Zhang S, Brisson E, Clavel F, Lowy I, et al. Expression of a Tat-inducible herpes simplex virus-thymidine kinase gene protects acyclovir-treated CD4 cells from HIV-1 spread by conditional suicide and inhibition of reverse transcription. Virology. 1995;206:495-503.
12. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther. 2000;11:2389-2401.
13. Smythe WR, Hwang HC, Amin KM, Eck SL, Davidson BL, Wilson JM, et al. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res. 1994;54:2055-2059.
14. Molnar-Kimber KL, Sterman DH, Chang M, Kang EH, ElBash M, Lanuti M, et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther. 1998;9:2121-2133.
15. Schwarzenberger P, Harrison L, Weinacker A, Marrogi A, Byrne P, Ramesh R, et al. The treatment of malignant mesothelioma with a gene modified cancer cell line: a phase I study. Hum Gene Ther. 1998;9:2641-2649.
16. Harrison Jr LH, Schwarzenberger PO, Byrne PS, Marrogi AJ, Kolls JK, McCarthy KE. Gene-modified PA1-Stk cells home to tumor sites in patients with malignant pleural mesothelioma. Ann Thorac Surg. 2000;70:407-411.
17. Sterman DH, Molnar-Kimber K, Iyengar T, Chang M, Lanuti M, Amin KM, et al. A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma. Cancer Gene Ther. 2000;7:1511-1518.
18. Klatzmann D, Valery CA, Bensimon G, Marro B, Boyer O, Mokhtari K, et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther. 1998;9:2595-2604.
19. Trask TW, Trask RP, Aguilar-Cordova E, Shine HD, Wyde PR, Goodman JC, et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther. 2000;1:195-203.
20. Shand N, Weber F, Mariani L, Bernstein M, Gianella-Borradori A, Long Z, et al. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GL1328 European-Canadian Study Group. Hum Gene Ther. 1999;10:2325-2335.
21. Alvarez RD, Gomez-Navarro J, Wang M, Barnes MN, Strong TV, Arani RB, et al. Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther. 2000;2:524-530.
22. Hasenburg A, Tong XW, Rojas-Martinez A, Nyberg-Hoffman C, Kieback CC, Kaplan A, et al. Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther. 2000;7:839-844.
23. Shalev M, Kadmon D, Teh BS, Butler EB, Aguilar-Cordova E, Thompson TC, et al. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol. 2000;163:1747-1750.
24. Herman JR, Adler HL, Aguilar-Cordova E, Rojas-Martinez A, Woo S, Timme TL, et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther. 1999;10:1239-1249.
25. Morris JC, Ramsey WJ, Wildner O, Muslow HA, Aguilar-Cordova E, Blaese RM. A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV.RSV-tk) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma. Hum Gene Ther. 2000;11:487-503.
26. Lambright ES, Amin K, Wiewrodt R, Force SD, Lanuti M, Propert KJ, et al. Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy. Gene Ther. 2001;8:946-953.
27. Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT. Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol. 1996;14:1574-1578.
28. Black ME and Loeb LA. Random sequence mutagenesis for the generation of active enzymes. Methods Mol Biol. 1996;57:335-349.
29. Black ME, Kokoris MS, Sabo P. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res. 2001;61:3022-3026.
30. Kokoris MS, Sabo P, Adman ET, Black ME. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene Therapy 1999;6:1415-1426.
31. Kokoris MS, Sabo P, Black ME. In vitro evaluation of mutant HSV-1 thymidine kinases for suicide gene therapy. Anti Cancer Res. 2000;20:959-963.
32. Qiao J, Black ME, Caruso M. Enhanced ganciclovir killing and bystander effect of human tumor cells transduced with a retroviral vector carrying a herpes simplex virus thymidine kinase gene mutant. Hum Gene Ther. 2000;11:1569-1576.
33. Pantuck AJ, Matherly J, Zisman A, Nguyen D, Berger F, Gambhir SS, et al. Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants. Hum Gene Ther. 2002;13:777-789.
34. Lanuti M, Gao GP, Force SD, Chang MY, El Kouri C, Amin KM, et al. Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy. Hum Gene Ther. 1999;10:463-475.
35. Engelhardt JF, Yang Y, Stratford-Perricaudet LD, Allen ED, Kozarsky K, Perricaudet M, et al. Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses. Nat Genet. 1993;4:27-34.
36. Elshami AA, Saavedra A, Zhang H, Kucharczuk JC, Spray DC, Fishman GI, et al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 1996;3:85-92.
37. Black ME and Loeb LA. Identification of important residues within the putative nucleoside binding site of HSV-1 thymidine kinase by random sequence selection: analysis of selected mutants in vitro. Biochemistry. 1993;32:11618-11626.
38. Gambhir SS, Bauer E, Black ME, Liang Q, Kokoris MS, Barrio JR, et al. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci USA. 2000;97:2785-2790.